Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

Vincenza Calvaruso, Anna Licata, Salvatore Petta, Vito Di Marco, Ciro Celsa, Calogero Camma', Antonio Craxi, Giuseppe Cabibbo, Giuseppe Alaimo, Francesco Benanti, Gaetano Scifo, Salvatore Madonia, Giovanni Raimondo, Anna Licata, Alfonso Averna, Marco Distefano, Maria Antonietta Di Rosolini, Giovanni Mazzola, Tullio Prestileo, Maria Rita CannavòLicia Larocca, Fabio Cartabellotta, Ignazio Scalisi, Giuseppe Malizia, Irene Cacciola, Maurizio Russello, Gaetano Bertino, Franco Trevisani, Giovanni Squadrito, Bianca Magro, Francesca Rini, Nicola Alessi

Risultato della ricerca: Other

8 Citazioni (Scopus)

Abstract

Background &amp; aims: The effectiveness of direct-acting antivirals (DAAs) against hepatitis C virus (HCV) after successful treatment of early hepatocellular carcinoma (HCC) has been studied extensively. However, the benefit in terms of overall survival (OS) remains to be conclusively demonstrated. The aim of this study was to assess the impact of DAAs on OS, HCC recurrence, and hepatic decompensation.Methods: We enrolled prospectively 163 consecutive patients with HCV-related cirrhosis and at first diagnosis of early Barcelona Clinic Liver Cancer (BCLC) 0/A HCC who had achieved a complete radiologic response after curative resection or ablation, subsequently treated with DAAs. DAA-untreated patients from ITA.LI.CA. cohort (n = 328) served as controls. After propensity-score matching, outcomes of 102 DAA-treated (DAA group) and 102 DAA-untreated patients (No DAA group) were compared.Results: In DAA group, 7/102 patients (6.9%) died, HCC recurred in 28/102 patients (27.5%) and hepatic decompensation occurred in 6/102 patients (5.9%), after a mean follow-up of 21.4 months. OS was significantly higher in DAA group compared with No DAA group (hazard ratio [HR] = 0.39; 95% confidence Interval [CI] = 0.17–0.91, p = 0.03). HCC recurrence was not significantly different between DAA and No DAA groups (HR = 0.70; 95%CI = 0.44–1.13, p = 0.15). A significant reduction in the rate of hepatic decompensation was observed in DAA group compared with No DAA group (HR = 0.32; 95%CI = 0.13-0.84, p = 0.02). In DAA group, sustained virologic response was a significant predictor of overall survival (HR 0.02, 95%CI 0.00–0.19, p < 0.001), HCC recurrence (HR 0.25, 95%CI 0.11–0.57, p < 0.001) and hepatic decompensation (HR 0.12, 95%CI 0.02-0.38, p = 0.02).Conclusions: In patients with HCV-related cirrhosis and previous successful treatment of early HCC, DAAs significantly improved OS compared with No DAA treatment.
Lingua originaleEnglish
Paginee36-e37
Numero di pagine2
Stato di pubblicazionePublished - 2019

Fingerprint

Hepacivirus
Antiviral Agents
Hepatocellular Carcinoma
Survival
Therapeutics
Confidence Intervals
Liver
Recurrence
Fibrosis
Propensity Score
Liver Neoplasms

All Science Journal Classification (ASJC) codes

  • Hepatology

Cita questo

Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. / Calvaruso, Vincenza; Licata, Anna; Petta, Salvatore; Di Marco, Vito; Celsa, Ciro; Camma', Calogero; Craxi, Antonio; Cabibbo, Giuseppe; Alaimo, Giuseppe; Benanti, Francesco; Scifo, Gaetano; Madonia, Salvatore; Raimondo, Giovanni; Licata, Anna; Averna, Alfonso; Distefano, Marco; Di Rosolini, Maria Antonietta; Mazzola, Giovanni; Prestileo, Tullio; Cannavò, Maria Rita; Larocca, Licia; Cartabellotta, Fabio; Scalisi, Ignazio; Malizia, Giuseppe; Cacciola, Irene; Russello, Maurizio; Bertino, Gaetano; Trevisani, Franco; Squadrito, Giovanni; Magro, Bianca; Rini, Francesca; Alessi, Nicola.

2019. e36-e37.

Risultato della ricerca: Other

Calvaruso, V, Licata, A, Petta, S, Di Marco, V, Celsa, C, Camma', C, Craxi, A, Cabibbo, G, Alaimo, G, Benanti, F, Scifo, G, Madonia, S, Raimondo, G, Licata, A, Averna, A, Distefano, M, Di Rosolini, MA, Mazzola, G, Prestileo, T, Cannavò, MR, Larocca, L, Cartabellotta, F, Scalisi, I, Malizia, G, Cacciola, I, Russello, M, Bertino, G, Trevisani, F, Squadrito, G, Magro, B, Rini, F & Alessi, N 2019, 'Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients', pagg. e36-e37.
Calvaruso, Vincenza ; Licata, Anna ; Petta, Salvatore ; Di Marco, Vito ; Celsa, Ciro ; Camma', Calogero ; Craxi, Antonio ; Cabibbo, Giuseppe ; Alaimo, Giuseppe ; Benanti, Francesco ; Scifo, Gaetano ; Madonia, Salvatore ; Raimondo, Giovanni ; Licata, Anna ; Averna, Alfonso ; Distefano, Marco ; Di Rosolini, Maria Antonietta ; Mazzola, Giovanni ; Prestileo, Tullio ; Cannavò, Maria Rita ; Larocca, Licia ; Cartabellotta, Fabio ; Scalisi, Ignazio ; Malizia, Giuseppe ; Cacciola, Irene ; Russello, Maurizio ; Bertino, Gaetano ; Trevisani, Franco ; Squadrito, Giovanni ; Magro, Bianca ; Rini, Francesca ; Alessi, Nicola. / Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. 2 pag.
@conference{a148af6112954b309228255df8af1937,
title = "Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients",
abstract = "Background & aims: The effectiveness of direct-acting antivirals (DAAs) against hepatitis C virus (HCV) after successful treatment of early hepatocellular carcinoma (HCC) has been studied extensively. However, the benefit in terms of overall survival (OS) remains to be conclusively demonstrated. The aim of this study was to assess the impact of DAAs on OS, HCC recurrence, and hepatic decompensation.Methods: We enrolled prospectively 163 consecutive patients with HCV-related cirrhosis and at first diagnosis of early Barcelona Clinic Liver Cancer (BCLC) 0/A HCC who had achieved a complete radiologic response after curative resection or ablation, subsequently treated with DAAs. DAA-untreated patients from ITA.LI.CA. cohort (n = 328) served as controls. After propensity-score matching, outcomes of 102 DAA-treated (DAA group) and 102 DAA-untreated patients (No DAA group) were compared.Results: In DAA group, 7/102 patients (6.9{\%}) died, HCC recurred in 28/102 patients (27.5{\%}) and hepatic decompensation occurred in 6/102 patients (5.9{\%}), after a mean follow-up of 21.4 months. OS was significantly higher in DAA group compared with No DAA group (hazard ratio [HR] = 0.39; 95{\%} confidence Interval [CI] = 0.17–0.91, p = 0.03). HCC recurrence was not significantly different between DAA and No DAA groups (HR = 0.70; 95{\%}CI = 0.44–1.13, p = 0.15). A significant reduction in the rate of hepatic decompensation was observed in DAA group compared with No DAA group (HR = 0.32; 95{\%}CI = 0.13-0.84, p = 0.02). In DAA group, sustained virologic response was a significant predictor of overall survival (HR 0.02, 95{\%}CI 0.00–0.19, p < 0.001), HCC recurrence (HR 0.25, 95{\%}CI 0.11–0.57, p < 0.001) and hepatic decompensation (HR 0.12, 95{\%}CI 0.02-0.38, p = 0.02).Conclusions: In patients with HCV-related cirrhosis and previous successful treatment of early HCC, DAAs significantly improved OS compared with No DAA treatment.",
author = "Vincenza Calvaruso and Anna Licata and Salvatore Petta and {Di Marco}, Vito and Ciro Celsa and Calogero Camma' and Antonio Craxi and Giuseppe Cabibbo and Giuseppe Alaimo and Francesco Benanti and Gaetano Scifo and Salvatore Madonia and Giovanni Raimondo and Anna Licata and Alfonso Averna and Marco Distefano and {Di Rosolini}, {Maria Antonietta} and Giovanni Mazzola and Tullio Prestileo and Cannav{\`o}, {Maria Rita} and Licia Larocca and Fabio Cartabellotta and Ignazio Scalisi and Giuseppe Malizia and Irene Cacciola and Maurizio Russello and Gaetano Bertino and Franco Trevisani and Giovanni Squadrito and Bianca Magro and Francesca Rini and Nicola Alessi",
year = "2019",
language = "English",
pages = "e36--e37",

}

TY - CONF

T1 - Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

AU - Calvaruso, Vincenza

AU - Licata, Anna

AU - Petta, Salvatore

AU - Di Marco, Vito

AU - Celsa, Ciro

AU - Camma', Calogero

AU - Craxi, Antonio

AU - Cabibbo, Giuseppe

AU - Alaimo, Giuseppe

AU - Benanti, Francesco

AU - Scifo, Gaetano

AU - Madonia, Salvatore

AU - Raimondo, Giovanni

AU - Licata, Anna

AU - Averna, Alfonso

AU - Distefano, Marco

AU - Di Rosolini, Maria Antonietta

AU - Mazzola, Giovanni

AU - Prestileo, Tullio

AU - Cannavò, Maria Rita

AU - Larocca, Licia

AU - Cartabellotta, Fabio

AU - Scalisi, Ignazio

AU - Malizia, Giuseppe

AU - Cacciola, Irene

AU - Russello, Maurizio

AU - Bertino, Gaetano

AU - Trevisani, Franco

AU - Squadrito, Giovanni

AU - Magro, Bianca

AU - Rini, Francesca

AU - Alessi, Nicola

PY - 2019

Y1 - 2019

N2 - Background & aims: The effectiveness of direct-acting antivirals (DAAs) against hepatitis C virus (HCV) after successful treatment of early hepatocellular carcinoma (HCC) has been studied extensively. However, the benefit in terms of overall survival (OS) remains to be conclusively demonstrated. The aim of this study was to assess the impact of DAAs on OS, HCC recurrence, and hepatic decompensation.Methods: We enrolled prospectively 163 consecutive patients with HCV-related cirrhosis and at first diagnosis of early Barcelona Clinic Liver Cancer (BCLC) 0/A HCC who had achieved a complete radiologic response after curative resection or ablation, subsequently treated with DAAs. DAA-untreated patients from ITA.LI.CA. cohort (n = 328) served as controls. After propensity-score matching, outcomes of 102 DAA-treated (DAA group) and 102 DAA-untreated patients (No DAA group) were compared.Results: In DAA group, 7/102 patients (6.9%) died, HCC recurred in 28/102 patients (27.5%) and hepatic decompensation occurred in 6/102 patients (5.9%), after a mean follow-up of 21.4 months. OS was significantly higher in DAA group compared with No DAA group (hazard ratio [HR] = 0.39; 95% confidence Interval [CI] = 0.17–0.91, p = 0.03). HCC recurrence was not significantly different between DAA and No DAA groups (HR = 0.70; 95%CI = 0.44–1.13, p = 0.15). A significant reduction in the rate of hepatic decompensation was observed in DAA group compared with No DAA group (HR = 0.32; 95%CI = 0.13-0.84, p = 0.02). In DAA group, sustained virologic response was a significant predictor of overall survival (HR 0.02, 95%CI 0.00–0.19, p < 0.001), HCC recurrence (HR 0.25, 95%CI 0.11–0.57, p < 0.001) and hepatic decompensation (HR 0.12, 95%CI 0.02-0.38, p = 0.02).Conclusions: In patients with HCV-related cirrhosis and previous successful treatment of early HCC, DAAs significantly improved OS compared with No DAA treatment.

AB - Background & aims: The effectiveness of direct-acting antivirals (DAAs) against hepatitis C virus (HCV) after successful treatment of early hepatocellular carcinoma (HCC) has been studied extensively. However, the benefit in terms of overall survival (OS) remains to be conclusively demonstrated. The aim of this study was to assess the impact of DAAs on OS, HCC recurrence, and hepatic decompensation.Methods: We enrolled prospectively 163 consecutive patients with HCV-related cirrhosis and at first diagnosis of early Barcelona Clinic Liver Cancer (BCLC) 0/A HCC who had achieved a complete radiologic response after curative resection or ablation, subsequently treated with DAAs. DAA-untreated patients from ITA.LI.CA. cohort (n = 328) served as controls. After propensity-score matching, outcomes of 102 DAA-treated (DAA group) and 102 DAA-untreated patients (No DAA group) were compared.Results: In DAA group, 7/102 patients (6.9%) died, HCC recurred in 28/102 patients (27.5%) and hepatic decompensation occurred in 6/102 patients (5.9%), after a mean follow-up of 21.4 months. OS was significantly higher in DAA group compared with No DAA group (hazard ratio [HR] = 0.39; 95% confidence Interval [CI] = 0.17–0.91, p = 0.03). HCC recurrence was not significantly different between DAA and No DAA groups (HR = 0.70; 95%CI = 0.44–1.13, p = 0.15). A significant reduction in the rate of hepatic decompensation was observed in DAA group compared with No DAA group (HR = 0.32; 95%CI = 0.13-0.84, p = 0.02). In DAA group, sustained virologic response was a significant predictor of overall survival (HR 0.02, 95%CI 0.00–0.19, p < 0.001), HCC recurrence (HR 0.25, 95%CI 0.11–0.57, p < 0.001) and hepatic decompensation (HR 0.12, 95%CI 0.02-0.38, p = 0.02).Conclusions: In patients with HCV-related cirrhosis and previous successful treatment of early HCC, DAAs significantly improved OS compared with No DAA treatment.

UR - http://hdl.handle.net/10447/350591

M3 - Other

SP - e36-e37

ER -